CN107001430A - 癌症和皮肤病变治疗 - Google Patents

癌症和皮肤病变治疗 Download PDF

Info

Publication number
CN107001430A
CN107001430A CN201580064634.6A CN201580064634A CN107001430A CN 107001430 A CN107001430 A CN 107001430A CN 201580064634 A CN201580064634 A CN 201580064634A CN 107001430 A CN107001430 A CN 107001430A
Authority
CN
China
Prior art keywords
hpv
cancer
dosage
given
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580064634.6A
Other languages
English (en)
Chinese (zh)
Inventor
蒂姆·艾恩尼德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weekes Harper Is A LLC
Original Assignee
Weekes Harper Is A LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Weekes Harper Is A LLC filed Critical Weekes Harper Is A LLC
Publication of CN107001430A publication Critical patent/CN107001430A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201580064634.6A 2014-10-24 2015-10-23 癌症和皮肤病变治疗 Pending CN107001430A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068332P 2014-10-24 2014-10-24
US62/068,332 2014-10-24
PCT/US2015/057150 WO2016065281A1 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Publications (1)

Publication Number Publication Date
CN107001430A true CN107001430A (zh) 2017-08-01

Family

ID=55761638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580064634.6A Pending CN107001430A (zh) 2014-10-24 2015-10-23 癌症和皮肤病变治疗

Country Status (15)

Country Link
US (1) US10238729B2 (enExample)
EP (1) EP3209676A4 (enExample)
JP (1) JP6663438B2 (enExample)
KR (1) KR102285401B1 (enExample)
CN (1) CN107001430A (enExample)
AU (1) AU2015335652B2 (enExample)
BR (1) BR112017008280A2 (enExample)
CA (1) CA2965498A1 (enExample)
CL (1) CL2017001008A1 (enExample)
IL (1) IL251825B2 (enExample)
MX (1) MX395186B (enExample)
MY (1) MY195018A (enExample)
PH (1) PH12017500754A1 (enExample)
SG (1) SG11201703262UA (enExample)
WO (1) WO2016065281A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017223970B2 (en) * 2016-02-27 2022-01-27 Hpvvax, Llc Method and composition for treating cancer or skin lesion using a vaccine

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087614A2 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2003078455A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus like particle from papillomavirus and their use in vaccine
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
US20100189744A1 (en) * 2007-03-09 2010-07-29 Bryan Janine T Papillomavirus vaccine compositions
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
CN101890160A (zh) * 2009-04-28 2010-11-24 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
US20120087937A1 (en) * 2009-06-25 2012-04-12 Brigitte Desiree Alberte Colau Novel compositions
US20120093821A1 (en) * 2009-04-10 2012-04-19 The John Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
JP2013512914A (ja) * 2009-12-04 2013-04-18 コンセヨ ナショナル デ インベスティガシオン シエンティフィカ イ テクニカ ヒトパピローマウイルス（ｈｐｖ）により発症された腫瘍性又は癌性病変に対するワクチン、処置、用途及び方法
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
US20140323437A1 (en) * 2011-06-06 2014-10-30 Chevron Phillips Chemical Company Lp Use of Metallocene Compounds for Cancer Treatment
US20150110824A1 (en) * 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
US20150299197A1 (en) * 2013-03-14 2015-10-22 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354662T1 (de) * 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
ATE503492T1 (de) 2002-12-20 2011-04-15 Glaxosmithkline Biolog Sa Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
CN101530612A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 16型重组人乳头瘤病毒疫苗
US20110110979A1 (en) 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
WO2010147268A1 (ko) 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
US9974849B2 (en) 2013-10-13 2018-05-22 Bioventures, Llc Human Papilloma virus therapeutic vaccine

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087614A2 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2003078455A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus like particle from papillomavirus and their use in vaccine
US20100189744A1 (en) * 2007-03-09 2010-07-29 Bryan Janine T Papillomavirus vaccine compositions
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
US20120093821A1 (en) * 2009-04-10 2012-04-19 The John Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
CN101890160A (zh) * 2009-04-28 2010-11-24 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
US20120087937A1 (en) * 2009-06-25 2012-04-12 Brigitte Desiree Alberte Colau Novel compositions
JP2013512914A (ja) * 2009-12-04 2013-04-18 コンセヨ ナショナル デ インベスティガシオン シエンティフィカ イ テクニカ ヒトパピローマウイルス（ｈｐｖ）により発症された腫瘍性又は癌性病変に対するワクチン、処置、用途及び方法
US20140323437A1 (en) * 2011-06-06 2014-10-30 Chevron Phillips Chemical Company Lp Use of Metallocene Compounds for Cancer Treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
US20150110824A1 (en) * 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
US20150299197A1 (en) * 2013-03-14 2015-10-22 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BENJAMIN S. DANIEL 等: "Complete Resolution of Chronic Multiple Verruca Vulgaris Treated With Quadrivalent Human Papillomavirus Vaccine", 《JAMA DERMATOL》 *
CHIEN-FU HUNG 等: "Therapeutic human papillomavirus vaccines: current clinical trials and future directions", 《EXPERT OPIN BIOL THER》 *
KALPANA DEVARAJ 等: "DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA", 《CRIT REV ORAL BIOL MED》 *
LL VILLA 等: "High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up", 《BRITISH JOURNAL OF CANCER》 *
SABRINA E. VINZON 等: "Protective Vaccination against Papillomavirus-Induced Skin Tumors under Immunocompetent and Immunosuppressive Conditions: A Preclinical Study Using a Natural Outbred Animal Model", 《PLOS PATHOG》 *
SABRINA E. VINZONA 等: "HPV vaccination for prevention of skin cancer", 《HUMAN VACCINES & IMMUNOTHERAPEUTICS》 *
SUPRIYA S. VENUGOPAL 等: "Recalcitrant Cutaneous Warts Treated With Recombinant Quadrivalent Human Papillomavirus Vaccine (Types 6, 11, 16, and 18) in a Developmentally Delayed, 31-Year-Old White Man", 《ARCH DERMATOL》 *

Also Published As

Publication number Publication date
SG11201703262UA (en) 2017-05-30
CL2017001008A1 (es) 2017-11-24
PH12017500754A1 (en) 2017-10-30
CA2965498A1 (en) 2016-04-28
KR102285401B1 (ko) 2021-08-02
AU2015335652B2 (en) 2020-07-02
MX2017005418A (es) 2017-11-30
BR112017008280A2 (pt) 2018-01-02
AU2015335652A1 (en) 2017-05-25
IL251825A0 (en) 2017-06-29
IL251825B1 (en) 2023-05-01
US20160114023A1 (en) 2016-04-28
IL251825B2 (en) 2023-09-01
WO2016065281A1 (en) 2016-04-28
EP3209676A4 (en) 2018-03-28
JP6663438B2 (ja) 2020-03-11
JP2017531699A (ja) 2017-10-26
KR20170072279A (ko) 2017-06-26
MX395186B (es) 2025-03-21
EP3209676A1 (en) 2017-08-30
MY195018A (en) 2023-01-03
US10238729B2 (en) 2019-03-26

Similar Documents

Publication Publication Date Title
Abeck et al. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children
Tsai Clinical cancer chemoprevention: From the hepatitis B virus (HBV) vaccine to the human papillomavirus (HPV) vaccine
JP2014506562A5 (ja) 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用
CN105597092A (zh) 含有白介素15的防治hpv感染的疫苗喷雾剂
KR20220140901A (ko) Hpv 백신
Ding et al. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer
JP2023110038A (ja) ワクチンを使用して癌または皮膚病変を治療するための方法および組成物
Filipić et al. Human papillomaviruses and cervical cancer from the perspective of the World Health Organisation initiative for cervical cancer elimination
JP6663438B2 (ja) 癌および皮膚病変の治療
May HPV vaccination-a paradigm shift in public health
US20100285058A1 (en) Dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
Devadasan et al. HPV vaccines–A game changer for preventing HPV-related cancers
US20230048144A1 (en) Hpv vaccine
HK1241898A1 (en) Cancer and skin lesion treatment
Abdulsalam et al. Role of HPV vaccines in multiple recalcitrant warts treatment
JP2017531699A5 (enExample)
US20180250378A1 (en) Combination of therapeutic vaccine and pd-1-related blockade for treating human papillomavirus-associated diseases
US10512683B2 (en) Combination therapies for human papillomavirus-associated diseases comprising administration of therapeutic vaccine and recombinant virus vector
Schauner et al. Bivalent HPV recombinant vaccine (Cervarix) for the prevention of cervical cancer
Fruscalzo et al. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development
Zawadka Human papilloma virus vaccination
Tezikov et al. Anogenital Warts: New Opportunities for Prevention
Udaya Kumar et al. Nasal vaccine as a booster shot: a viable solution to restrict pandemic?
Jorge et al. Update: HPV prevention
EA047059B1 (ru) Вакцина против hpv

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241898

Country of ref document: HK